USP30-AS1 has emerged as a critical biomarker in colon cancer progression and prognosis, demonstrating significant correlations with aggressive clinicopathological features including larger tumor size, lymph node metastasis, and advanced TNM stage, all indicative of poor clinical outcomes (Yang et al., 2019). Here, USP30 is linked to colonic neoplasm.